Matthew Wiley Sells 2,867 Shares of Definium Therapeutics (NASDAQ:DFTX) Stock

Posted by Francis Steltz on Jun 28th, 2026

Definium Therapeutics, Inc. (NASDAQ:DFTX – Get Free Report) insider Matthew Wiley sold 2,867 shares of the company’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $129,101.01. Following the transaction, the insider directly owned 174,633 shares in the company, valued at approximately $7,863,723.99. This trade represents a 1.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Definium Therapeutics Stock Performance

Shares of DFTX opened at $44.95 on Friday. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.15. Definium Therapeutics, Inc. has a 52-week low of $6.40 and a 52-week high of $47.01. The company has a 50-day simple moving average of $24.59 and a 200-day simple moving average of $19.36. The company has a market capitalization of $4.48 billion, a PE ratio of -18.05 and a beta of 2.37.

Definium Therapeutics (NASDAQ:DFTX – Get Free Report) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.23). Equities research analysts predict that Definium Therapeutics, Inc. will post -2.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Definium Therapeutics

Institutional investors have recently made changes to their positions in the stock. Cerity Partners LLC boosted its stake in shares of Definium Therapeutics by 2.4% during the second quarter. Cerity Partners LLC now owns 49,650 shares of the company’s stock valued at $322,000 after acquiring an additional 1,165 shares during the last quarter. Creative Planning raised its stake in Definium Therapeutics by 2.6% in the 2nd quarter. Creative Planning now owns 66,097 shares of the company’s stock valued at $429,000 after purchasing an additional 1,655 shares during the last quarter. Rathbones Group PLC lifted its holdings in Definium Therapeutics by 7.1% in the 3rd quarter. Rathbones Group PLC now owns 30,200 shares of the company’s stock valued at $356,000 after purchasing an additional 2,000 shares in the last quarter. Bay Rivers Group lifted its holdings in Definium Therapeutics by 14.3% in the 4th quarter. Bay Rivers Group now owns 16,001 shares of the company’s stock valued at $214,000 after purchasing an additional 2,000 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its stake in shares of Definium Therapeutics by 110.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after purchasing an additional 2,003 shares during the last quarter. 27.91% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on DFTX shares. Citigroup restated a “buy” rating on shares of Definium Therapeutics in a report on Monday, June 22nd. Leerink Partners set a $52.00 target price on Definium Therapeutics and gave the stock an “outperform” rating in a research report on Monday, June 22nd. Stifel Nicolaus set a $30.00 target price on Definium Therapeutics and gave the company a “buy” rating in a report on Thursday, April 16th. Robert W. Baird raised their price target on Definium Therapeutics from $37.00 to $57.00 and gave the company an “outperform” rating in a research report on Tuesday, June 23rd. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Definium Therapeutics in a research note on Monday, June 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Definium Therapeutics has a consensus rating of “Buy” and an average target price of $47.08.

Check Out Our Latest Stock Analysis on Definium Therapeutics

Key Stories Impacting Definium Therapeutics

Here are the key news stories impacting Definium Therapeutics this week:

Positive Sentiment: Definium said its Phase III depression program delivered positive results, a key catalyst that can support optimism about eventual approval and commercialization. Definium raises $805 million after positive Phase III depression data
Positive Sentiment: The company closed an upsized public offering, raising $805 million, which strengthens its balance sheet and reduces near-term financing risk. Definium Therapeutics Announces Closing of $805 Million Upsized Public Offering
Neutral Sentiment: Several insiders, including the CEO and CFO, sold shares at $45.03. Insider selling can sometimes pressure sentiment, but the transactions were relatively small compared with their remaining holdings. CEO insider filing
Neutral Sentiment: Market commentary and analyst writeups also pointed to the stock’s sharp move higher after the Phase III news, reinforcing the view that investors are reacting to the clinical-data catalyst. Why Definium Therapeutics, Inc.’s (DFTX) Stock Is Up 15.35%
Negative Sentiment: Heavy insider selling from multiple executives may temper enthusiasm, as some investors could interpret it as a sign management views the stock as fully valued near recent highs.

Definium Therapeutics Company Profile

(Get Free Report)

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.